Clinical trial · Observational
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Evaluation of Safety and Effectiveness of Senaparib in Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer: A Prospective Observational Real-World Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer (OvCa) | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Senaparib capsules(20mg) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence and severity of Treatment-Related Adverse Events (TRAEs) according to NCI CTCAE v5.0
- timeFrame
- 30 days after the last dose of fluzoparib
- description
- Incidence and severity of Treatment-Related Adverse Events (TRAEs) as assessed by the investigator.
Secondary outcomes (3)
- measure
- treatment patterns of senaparib
- timeFrame
- 2 years
- description
- the initial dose of senaprib 、incidence of dose reduction of senaparib 、treatment discontinuaiton of senaparib
- measure
- Progression free survival (PFS)
- timeFrame
- 6 years
- description
- Progression-free survival, defined as time from first administration senaparib to documented disease progression or death from any cause after baseline, whichever occurs first;. To assess clinical effectiveness of senaparib monotherapy or combination therapy involved in this study by assessment of progression free survival (PFS) in patients with Ovarian Cancer. Patients will be followed up once 3-6 months at least.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Sign informed consent and voluntarily join the study; * Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology; -≥ 18 years old; * The investigator determined that the patient could receive senaparib monotherapy or combination therapy; * For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of senaparib Exclusion Criteria: * There is evidence that the patient is a pregnant or lactating woman; * Participating in any research with intervention measures other than routine -clinical practice; * The researcher judges other situations that are not suitable for inclusion in the study;
References
Publications (0)
Data not yet available